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Abstract 9 
ITP is an organ specific autoimmune disorder characterised by a low platelet count whose cause is 10 
uncertain.  A possible factor is food intolerance, although much of the information linking this with 11 
ITP is anecdotal.  The role of food intolerance in ITP was studied by replacing a normal diet with an 12 
elemental diet (E028) but this did not increase platelet counts.   Clear differences, however, were 13 
apparent between the volatile organic compounds (VOCs) in the urine headspace of patients with ITP 14 
and those present in healthy volunteers, which leads to speculation that abnormal metabolic activity 15 
of the intestinal microbiome may be a factor causing ITP.  However further work is needed to confirm 16 
this.  There were also differences between the VOCs of patients on a normal diet and those on the 17 
elemental diet, and in this case, the VOCs involved are very likely to be of bacterial origin, as their 18 
production is affected by dietary manipulation. Many of these VOCs are known to be toxic. 19 
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1. Introduction 23 
1.1 Immune Thrombocytopenia (ITP) 24 
ITP is an organ specific autoimmune disorder (1) characterised by a low platelet count. In diagnostic 25 
terms, ITP is defined as a platelet count of ‘less than 100 x 109/L (100,000/µL)’ (2).  Its prevalence has 26 
been examined in a number of countries and ranges from 2.64 per 100,000 patients/year in Denmark 27 
to 9.5 per 100,000 in the USA.  A predominant number of cases in childhood are in males with this 28 
changing to middle-aged women in adulthood.  The overall ratio male to female ratio is thought to be 29 
1:1.9 (3i).  Most cases of ITP are classed as being idiopathic but some cases are secondary to coexisting 30 
conditions as mentioned in section 1.2 (4). 31 
1.2 Causes of ITP 32 
Numerous theories have been put forward as to the cause of ITP but a definitive answer remains 33 
elusive.   Definitive diagnosis of the condition is still extremely difficult and is often related to 34 
numerous other factors, for example SLE, HIV infection, hepatitis C, drug induced or Helicobacter 35 
pylori infection.  It also means that diagnosis is therefore usually made by exclusion of other disorders 36 
(3).  37 
One of the major hypotheses is that ITP is characterised by increased platelet destruction either by 38 
antibody mediated platelet destruction or platelet lysis due to cytotoxic T-lymphocytes (1,4,5).  39 
Another suggestion is ‘molecular mimicry’ which is defined as ‘similar structures shared by molecules 40 
produced by dissimilar genes’ (1).  Here, by a complementary mechanism, a pathogen (such as 41 
Helicobacter pylori or HIV) can induce cellular injury and release self-antigens.  This generates an 42 
immune response that cross-reacts with additional self-antigens which are genetically distinct. The 43 
theory is that a pathogen could induce antibody production in response to antigens that cross-react 44 
against various platelet glycoprotein antigens.  Therefore, specific antibodies might be capable of 45 
causing thrombocytopenia.  This mimicry of host proteins enables the pathogens to escape host 46 
surveillance (1,6,7).  The final major theory is that there is decreased platelet production.  In healthy 47 
people, when platelet production equals platelet destruction and consumption, a stable platelet count 48 
will occur (8).   In patients with ITP, shorter platelet lifespan is consistently seen.  One explanation for 49 
this is that some surface antigens that are co-expressed on platelets, megakaryocyte precursors, and 50 
megakaryocytes are recognised by autoantibodies.  Reduced platelet production is then assumed to 51 
be due to the direct effect of antibodies on the maturation of megakaryocytes or platelet release (6,9). 52 
Certainly ITP occurs by a number of complex processes involving multiple components of the immune 53 
system.  Apart from decreased platelet production, a continual ‘self-antigen-stimulated’ response 54 
ultimately leads to a deficiency in the central and/or peripheral tolerance (failure to mount an immune 55 
response to an antigen) which triggers an autoreactive lymphocyte response.  Evidence suggests that 56 
both environmental and genetic factors are the key to this issue (1). 57 
1.3 Linking ITP to food intolerance? 58 
Food intolerance has been suggested as a cause of ITP, however much of the information linking the 59 
two is anecdotal.  The link has been recognised and documented in a few cases as early as 1936 (10), 60 
but little has been documented specifically related to ITP and food intolerance between then and now, 61 
except in individual case reports (11,12,13). 62 
Most recently, in 2012, a case study was published in the Lancet by Achterbergh, et al. which detailed 63 
the case of a 70 year old man who was admitted with vomiting, nausea and fever and found to have 64 
a platelet count of 32,000 per µL.  After investigation and a second admission, the causative factor 65 
was determined to be the walnut, and to test this, a subsequent walnut challenge was carried out.   66 
His initial platelet count was 233,000 per µL, and 4 hours after being given 100g of walnuts, he 67 
developed fever, nausea and vomiting, bled from a small wound and developed large haematomas 68 
around venepuncture sites.  Approximately 15 hours after ingestion his platelet count had dropped to 69 
4,000 per µL. Following exclusion of nuts from his diet he had no further episodes and maintained a 70 
normal platelet count.  Although walnuts were clearly related to the sudden drop in platelet count, 71 
this remains a rare case, and is likely the result of an acute ITP episode.  72 
Bacteria produce numerous metabolites, some of which are volatile, others which are semi volatile or 73 
not volatile at all.  These may all vary depending on the food sources available in the gut.  In addition, 74 
as the human body produces a steady stream of metabolic waste (ammonia, lactic acid, urea, bilirubin 75 
etc.) and exotoxins (produced by the microbiota in the gut) the body carries out biotransformation in 76 
the liver to remove toxins by converting them to less toxic substances which may then be excreted in 77 
urine or the bile (14).   78 
It is to be expected, therefore, that these volatile organic compounds (VOCs) may be detected in urine 79 
headspace.  Approximately 279 VOCs have been identified in urine in apparently healthy individuals 80 
(14i).  Urinary VOCs for example, have been shown to discriminate tuberculosis patients from healthy 81 
subjects (14ii) and some have shown differences in the female reproductive cycle during ovulation 82 
(14iii). The headspace of urine of a group of ITP patients and healthy control subjects were therefore 83 
studied using selected ion flow tube mass spectrometry (SIFT-MS) to look at initial overall differences 84 
between urine headspace from the ITP and healthy control groups; this was then extended to seeing 85 
how the urinary VOC profile was affected by diet. 86 
The data were compared using univariate and multivariate statistical analysis. The aim of this project 87 
was to discover if ITP subjects and healthy controls could be easily differentiated by looking at urinary 88 
profiles using SIFT-MS and to determine whether food intolerance is involved in ITP. 89 
2. Methods 90 
2.1 Initial Phase: Patient recruitment 91 
The initial volunteer population group for this part of the study was recruited via the ITP Support 92 
Association. 93 
Ethical permission for the study was obtained from the Cambridge Local Research Ethics committee 94 
(LREC) reference 11/EE/0084. Patients of either sex aged 18-65 years suffering from chronic primary 95 
immune thrombocytopenia were recruited.   96 
The diagnosis of ITP was based on the criteria set out by Rodeghiero et al (2009) with a platelet count 97 
of less than 100,000/µL, and a history of this condition for at least 12 months.  Patients who had 98 
undergone splenectomy were included, provided the operation was not recent and that they were 99 
taking no other antibiotics than penicillin to reduce the risk of infection.  Patients on other drugs were 100 
included if their platelet count remained low and provided that the drug was started before the 101 
longest time to peak response quoted by Rodeghiero et al., 2009 and that they were willing to 102 
continue that treatment until their participation in the trial was concluded. 103 
On recruitment, a urine sample was taken and was tested with a multistix® urianalysis (Siemens UK) 104 
test before being frozen and sent for SIFT-MS headspace analysis. 105 
A healthy control group of 50 people aged 18-65 years was also selected; these had the same initial 106 
tests performed.  107 
Subjects were excluded from the study according to the following criteria: 108 
a) Subjects outside 18-65 yrs 109 
b) Pregnancy and lactation 110 
c) Acute thrombocytopenia 111 
d) Thrombocytopenia related to underlying disease or drugs 112 
e) Patients who have received broad spectrum antibiotics in the previous 6 weeks  113 
f) Patients who had started treatment with Rituximab, Danazol, Eltrombopag or Azathioprine in 114 
the previous 6 months 115 
g) Patients who had started treatment with Corticosteroids, Vincristine or AMG531 116 
(Romiplostim) in the previous 8 weeks 117 
h) Patients who have undergone splenectomy within previous 8 weeks 118 
i) Patients known to have Inflammatory Bowel Disease (IBD) or Coeliac disease 119 
2.2 Sampling 120 
Participants were recruited from around the UK and travelled from their homes to attended 121 
Addenbrooke’s Hospital.  Here they provided written informed consent.  They were asked to complete 122 
a symptom questionnaire and provided a sample of urine and blood. The urine samples were collected 123 
in 20ml FisherbrandTM scintillation vials (Fisher Scientific, Loughborough) while the subjects were 124 
present at the hospital and were immediately frozen at -80°C.  All samples were anonymised and 125 
labelled with a specific number; the code was only known by the principal investigator (PI). Urine 126 
samples were frozen for a maximum of 3 months before being thawed and immediately tested.  Blood 127 
was taken into Thromboexact® (Sarstedt AG & Co, Germany) containers to ensure accuracy of platelet 128 
counts and was immediately transferred to the laboratory for testing. 129 
2.2.1 Demographics 130 
All initial samples were collected over a 12 month period.  The mean age in years (± s.d) of the healthy 131 
controls was 48.2 ± 10.9 with a percentage of female sex being 54.3%.  The mean age in years (± s.d) 132 
of the ITP volunteers was 47.6 ± 12.9 with the percentage female sex being 66.7%. 133 
From the initial ITP results, a group of participants with the lowest platelet counts throughout the 134 
whole ITP group were selected to undertake dietary modification using the elemental diet E028 extra 135 
(Nutricia, Trowbridge, UK).  A group of healthy controls also volunteered to limit their nutrition to 136 
elemental E028 extra for 7 days.   137 
2.3 Dietary modification - Elemental Diet 138 
Elemental 028 Extra diet is a nutritionally complete liquid formula containing a mix of essential and 139 
non-essential amino acids, a single fatty oil, minerals, maltodextrins, vitamins and trace elements. It 140 
was administered in 250ml ready-made cartons in a choice of flavours.  E028 Extra has been shown to 141 
be of therapeutic value in Crohn’s disease and refractory coeliac disease (15,16). 142 
Each participant gave a blood and urine sample taken prior to beginning the diet and had a 143 
consultation with a registered dietician to give advice on what the diet entailed, and what to expect.  144 
They were given written details of the diet and asked to complete a symptom diary.  E028 extra was 145 
introduced gradually in half quantities over the first few days and then fully for the rest of the 4-week 146 
period. A blood sample for platelet count was taken every week either by the patient’s General 147 
Practitioner (GP), or at Addenbrooke’s Hospital.  Urine samples were taken before the diet was started 148 
and after the diet was completed and were immediately frozen at -80°C before being sent for analysis 149 
by SIFT-MS. 150 
2.4 Control Group – Elemental Diet 151 
The healthy volunteers were people who were known to be healthy with no blood or gastrointestinal 152 
disorders or food intolerances. Due to time restrictions with the project and the difficulties 153 
encountered when being on the E028 Extra, only 3 members of the research team took part.  As these 154 
subjects had to follow their normal lives, it was not appropriate for them to continue E028 Extra for 155 
the full four weeks, and they remained on it for 5-8 days. 156 
A blood sample was taken prior to starting the diet and on the last day of the diet.  A urine sample 157 
was also taken prior to starting the diet and on the last day. Following the collection of urine samples, 158 
they were frozen at -80°C before being processed using SIFT-MS. 159 
2.5 Urine Sample Preparation 160 
Urine samples were removed from the freezer and placed in a room temperature environment to fully 161 
defrost.  To 5ml of each sample, which was pipetted from the scintillation vial, 125µl of 13M 162 
hydrochloric acid was added to aid in the generation of VOCs (20).  Exactly 3g of sodium chloride was 163 
added to the empty Nalophan sample bags (Foodpak®) that had been made up to 40cm long and 164 
sealed at one end with a cable tie.  The acidified urine was then added to each bag.   The Nalophan 165 
bag was then sealed around silicone tubing with a Swagelok® fitting, and the urine mixed by gently 166 
shaking to ensure even distribution of the acid and the salt. Each sample bag was then filled with 167 
hydrocarbon-free air and sealed with a Swagelok® nut. 168 
The samples were placed into an incubator at 40°C. The door was sealed and then the samples were 169 
left for one hour to generate headspace prior to headspace analysis by selected ion flow tube mass 170 
spectrometry (SIFT-MS). 171 
2.6 SIFT-MS Analysis 172 
In this case a SIFT-MS MkII from PDZ Europa was used, with a flow rate through the heated capillary 173 
giving a pressure of 0.008 Torr in the flow tube. Samples were analysed for T5 x 6 at unit resolution. 174 
Full details of how SIFT-MS may be used to analyse trace gases and volatile organic compounds may 175 
be found elsewhere (18), however, a brief explanation is warranted here. In SIFT-MS, precursor ions 176 
(H3O+, NO+ and O2+) are generated in a microwave discharge and may then be selected by a quadrupole 177 
mass filter.  The selected ion is then injected into a fast flowing helium carrier gas, and down a flow 178 
tube.  A sample is then introduced into the flow tube at a rate of 15ml/min, and the precursor ion 179 
reacts with the trace gases and volatile organic compounds in the sample.  Each sample is analysed 180 
for 5 seconds, on 6 separate scans, giving a total of 30 seconds analysis on each scan.  The precursor 181 
and product ions in the carrier gas are separated in a second quadrupole mass spectrometer and 182 
subsequently counted in a detector.  Data may be obtained through scanning a spectrum at a user-183 
defined range of mass-to-charge ratio (m/z) values and quantification is carried out using a kinetics 184 
database stored in the instrument.  In this case the user defined m/z range was 10-140 m/z. 185 
2.7 Statistical Analysis 186 
Data were analysed using univariate and multivariate statistical techniques.  The univariate technique 187 
involved the non-parametric Mann-Whitney U test analysis because the data were not normally 188 
distributed.   Multivariate data analysis was performed by custom-built scripts written in MATLAB 189 
R2011a (MathWorks Inc., Nattick, USA) using functions from the PLS Toolbox (version 3.5, EigenVector 190 
Research Inc., USA).  A variety of multivariate statistics were tested to determine the most appropriate 191 
for these data sets. Prior to multivariate data analysis, data generated by the H3O+, NO+ and O2+ 192 
precursor ions were optionally combined into one large dataset. The intensity values at the range of 193 
m/z values within the data were normalised against the intensity values of the H3O+ precursor ions 194 
(m/z value of 19). The m/z values pertaining to the known adducts (isotopologues) of the H3O+ 195 
precursor ion were removed; these had the following m/z values: 19, 21, 32, 37, 39, 55, 57, 73, 75, 196 
and 91. If combined, then m/z values of 30, 34, 48 and 66 were also removed. Finally, m/z values 197 
pertaining to data columns consisting only of zeros were also removed.   198 
Exploratory data analysis using principal components analysis (19) revealed no outlying samples.  199 
Multivariate classification via partial least squares discriminant analysis (PLS-DA) was performed. This 200 
is a supervised pattern recognition technique in which the computer is trained to recognise patterns 201 
in the data that will help distinguish between low and high risk patients. To ensure a robust and 202 
confident result was attained, a two-step bootstrapping process was employed in an average 203 
performance of all models created.  To further improve the classification accuracy attained, feature 204 
selection via either the parametric Student t test (STT) or the non-parametric Wilcoxon T test (WTT), 205 
was performed prior to the classification. The number of features in each sample following feature 206 
selection via the student t test was 9.  The statistical significance of the classification accuracy was 207 
determined by performing permutation testing which involved randomising the class assignation 300 208 
times, and for each random assignation, the two-step bootstrapping process was performed. The 209 
statistical z-test was employed to determine the significance (p < 0.05) (20). 210 
3. Results 211 
3.1 Initial Platelet count 212 
Results of the platelet counts showed a highly significant difference between the ITP and the control 213 
groups.  Although the subject groups were relatively large, they were still assessed with non-214 
parametric testing as there were fewer than 100 samples in each group and were not normally 215 
distributed.   216 
The data were analysed using Mann Whitney U testing.  With this analysis the two sets of data were 217 
found to be significantly different.  The z-score was found to be -6.98 with a p-value of <0.00001.  All 218 
the control samples had normal platelet counts with a mean platelet count of 236,200 per µL and a 219 
range of 147,000-341,000 per µL.  The ITP volunteer group had a mean platelet count of 58,000 per 220 
µL with a range of 5,000- 281,000 per µL. 221 
There were some outliers in the ITP group which were closer to normal platelet levels.  These were 222 
117,000, 144,000 and 281,000 per µl and although these data are included in these initial results, all 223 
were subsequently excluded from the study. 224 
3.2 Platelet Counts before and after E028 Diet 225 
In total 10 volunteers with ITP and 3 healthy control volunteers went onto the E028 diet. Platelet 226 
counts were assessed prior to and after dietary modification with the E028 diet.   227 
When ITP platelet counts were assessed, no significant increase in platelet count occurred while on or 228 
initially after taking the E028 diet (Figure 1). 229 
3.4 Analysis of VOCs in Urine Headspace using SIFT-MS 230 
3.4.1 Univariate Analysis of urine headspace of whole cohort of ITP and control participants 231 
In total 35 controls and 42 ITP subjects were included in this study to compare the groups of ITP 232 
participants and healthy control participants.  Univariate analysis of urine headspace of the H3O+ data 233 
using the Mann-Whitney U test, found two m/z values to be significantly different between ITP 234 
sufferers and healthy controls.  These m/z values were m/z 18 and m/z 43.  Using box and whisker 235 
plots (Figure 2) these differences are shown.  These ions are likely to represent ammonia and 1 or 2 236 
propanol respectively. 237 
3.4.2 Multivariate Analysis of urine headspace of whole cohort of ITP and control participants 238 
When analysing the H3O+ data alone, it was found that PLS-DA in conjunction with feature selection 239 
via the Student t test (STT) offered the best result when comparing the headspace of urine from ITP 240 
suffers and healthy controls.  Overall the percentage of correctly classified (%CC) samples was 70% 241 
with a specificity of 53% and a sensitivity of 84%. The sensitivity suggests that SIFT-MS is able to show 242 
there are clear differences in the volatile metabolome of subjects with ITP. However, the relatively 243 
low specificity suggests that data pertaining to healthy control subjects is more complex; this could be 244 
attributed to some underlying features or a wide variation in the urinary volatile metabolome of 245 
healthy volunteers. The area under the ROC (AUROC) curve was calculated as 0.80. 246 
In order to determine whether the overall classification value was statistically significant, permutation 247 
testing was carried out (Figure 3) which involves randomising the class assignations 300 times. Though 248 
overlap between the two distributions exists, the z-test calculation, which compares the means of the 249 
distributions, rejected the null hypothesis thus suggesting that the %CC attained at 70% is statistically 250 
significant at the 95% confidence (p<0.05). Furthermore, the number of variables (m/z values) which 251 
were found to be significant following the Student t-test was 8 with the corresponding m/z values of 252 
34, 43, 53, 72, 74, 76, 89, and 112. The influential variables further indicated by the PLS-DA loadings 253 
(not shown) appear to be, m/z 43, m/z 53 and m/z 76. 254 
Of interest is that the PLS-DA loadings also showed that m/z 43 was in the opposite direction to the 255 
other m/z values. This can be interpreted that ITP sufferers had strong correlations with higher counts 256 
of m/z 43 using H3O+ and lower counts of m/z, 34, 53, 72, 74, 76, 89 and 112 than the control subjects. 257 
It also correlates with the earlier univariate analysis to show that m/z 43 is significant. 258 
Combination of the abundances from all three pre-cursor ions in conjunction with the normal 259 
approach of removing the precursor ions and their adducts had resulted in good performances by the 260 
PLS-DA models in conjunction with feature selection by both Wilcoxon T test and Student t-test (88% 261 
and 87% respectively). 262 
The classification accuracy of 88% pertaining to WTT (Control versus ITP) produced a specificity of 87% 263 
and a sensitivity of 89%, which is considerably better than just using H3O+ alone. 264 
The permutation testing demonstrated that the result was statistically significant and not due to 265 
chance. Furthermore, the PLS-DA loadings (not shown) suggests that the following m/z values could 266 
be influential to the distinction between ITP patients and healthy controls:  267 
• H3O+: 43, 46, 53, 70, 76, 89 268 
• NO+: 54, 56, 59, 76, 78, 92, 111 269 
• O2+: 31, 41, 54, 86, 105, 106 270 
 271 
3.5 Identifying the compounds related to m/z values 272 
A number of m/z values have been identified above.  The potential identifications indicated in table 1 273 
shows potential compounds these m/z values may relate to but this would need to be verified using 274 
GC/MS. 275 
The m/z values for products using the O2+ precursor ion are much more difficult to identify, and 276 
therefore would need another technique such as GC-MS for identification. 277 
These results demonstrate that there is a clear difference between urine headspace from ITP patients 278 
and healthy volunteers. 279 
3.6 Dietary Modification – E028 Diet 280 
3.6.1 Univariate Data H3O+ 281 
Although sample groups were small, some analysis was possible when looking at the differences that 282 
the E028 diet made on the headspace analysis of both the ITP sufferers and the healthy controls.  On 283 
comparing the SIFT-MS data, two compounds were found to be statistically significant in the ITP group 284 
of pre and post diet.  These were methanol and propanol.  Figure 4 and 5 illustrate the ITP group 285 
results for the VOC methanol along with the corresponding control group results.  Although the control 286 
group was too small to be statistically compared it is illustrated that the controls showed a similar 287 
pattern of reduction of methanol following E028 diet as in the ITP group. 288 
Individual ion data were also analysed and two m/z values were found to be statistically significant in 289 
the ITP group.  These were m/z 51 and 69.  These m/z values most likely represent methanol, with 290 
water hydrates (CH4OH.H+.H2O andCH4OH.H+.2H2O).  Table 2 illustrates these data. 291 
When propanol data were analysed it can be observed that in the ITP group, the concentration in 292 
parts-per-billion (ppb) in urine headspace decreases significantly after E028 diet.  Conversely in the 293 
control group, although not statistically proven, indicates an opposite pattern where the propanol 294 
levels increase after E028 diet (Figure 5). 295 
3.6.2 Multivariate statistical analysis 296 
Due to too few control subjects, the E028 diet data were only analysed for the ITP volunteers. Initial 297 
multivariate analysis used data from the H3O+ precursor ions. The method showing the best resulting 298 
classification was PLS-DA with WTT.  This had an overall correct classification of 80% with a specificity 299 
of 70% and a sensitivity of 90%. The AUROC was calculated to be 0.9360. Combining the precursor 300 
ions as previously described and subjecting to PLS-DA with WTT produced an overall classification 301 
(%CC) of 95% (95% specificity and 95% sensitivity). The calculated AUROC was 0.9554. 302 
This suggests that the effects of the E028 Extra via SIFT-MS and pattern recognition are very clearly 303 
visible, thus demonstrating the effect on urine headspace VOCs following elemental diet. 304 
4. Discussion 305 
This study investigated ITP and urine headspace changes in relation to dietary changes and food 306 
intolerance.  There were no increases in platelet counts when ITP subjects maintained an E028 Extra 307 
diet, implying that it was unlikely that ITP is caused by food intolerance.  This is in contrast to Crohn’s 308 
disease, where the E028 extra brings about long term remission of the condition and therefore long 309 
term dietary therapy is practicable (21). 310 
Although much research has been carried out looking at the effects certain drugs have in causing ITP, 311 
it is still unknown if these mechanisms could also explain why some foods may cause similar reactions.  312 
However, it has been noted that drug induced reactions can take up to 7 days to appear (22), which 313 
would imply a different reaction than foods as these have generally been reported, to occur very 314 
rapidly (23). 315 
Research looking at actual platelet counts in relation to food intolerance is limited and mostly relate 316 
to complementary therapies, supplements and drinks, rather than a full scale look at specific foods 317 
(24). It is difficult to know if there have been any other experiences of these type of results when 318 
looking at chronic ITP and not just isolated or acute episodes as is often reported as by Royer et al., in 319 
2010.  It is also unknown if diet or dietary modification has ever been assessed in relation to actual 320 
platelet count data.  321 
What could be hypothesised is that there are certain groups of people, or certain medical conditions 322 
that lead to a person having a predisposition for the way in which they process their food. This is then 323 
ultimately influenced by bacteria in the gut and may be related to factors including the type of bacteria 324 
in the population, the number of those bacteria and their responses to the food presented to them. 325 
4.1 Explaining significant m/z values 326 
Analysis of the headspace using SIFT-MS showed differences in propanol in ITP compared with healthy 327 
subjects, but cannot distinguish between 1-propanol, or 2-propanol.  Propanol is a fermentation 328 
product in the gut, for example and Hosseini et al in 2011 found that Clostridium neopropionicum X4 329 
was able to ferment (1-13C)-ethanol and CO2 to (2-13C)-Propanol, suggesting that this compound is 330 
potentially produced via fermentation by bacteria. 331 
Ions of m/z 18 and 36 most likely correspond to the compound ammonia.  Ammonia is ubiquitous in 332 
urine due to the fact it is a breakdown product of urea, and as a simple nitrogenous product it is of 333 
interest biologically as it can be used by living organisms for protein synthesis (25,26).  Bacteria can 334 
also utilise it for their nitrogen requirements and bacteria can also be major producers of ammonia 335 
too (27).  Ammonia can be found in many tissues in the body including muscle and kidneys but it also 336 
enters the circulation from the gastrointestinal tract.  During deamination, significant ammonia is 337 
released and endogenously it is also released by the kidney.  The third source is formed in the 338 
gastrointestinal tract by the action of amino-acid oxidase and urease derived from bacteria (28).  The 339 
micro-organisms responsible for urease activity include enterobacteria, bacterioides, clostridia and 340 
Klebsiellaaerobacter (29).   341 
Overall it is extremely difficult to pinpoint exactly why the ammonia levels were significantly different 342 
between ITP and healthy controls but again, one of the more likely causes is gut fermentation - 343 
considerable amounts of ammonia have been shown to be produced by bacteria from non-urea 344 
sources.  Ammonia has been shown to be a potentially toxic product of protein breakdown in the large 345 
intestine and it seems to be a compound that is repeatedly indicated in a number of diseased states 346 
(30).  Richardson suggests that a functional group on a ‘deaminative’ bacteria exists, which is similar 347 
to the ‘hyper-ammonia producing’ bacteria in the rumen of cattle and sheep, and that if these exist in 348 
the human colon they may have a similar significance with fermentation, and may also be manipulated 349 
via dietary modification (30).  This repetitive indication of the compound suggests it is not unique to 350 
any one disease and therefore would not alone, be useful as an indicator of a specific disease. 351 
Add bit here on breakdown of platelets? 352 
SIFT-MS analysis following dietary changes proved that the size of the sample groups were too small 353 
to offer convincing evidence of potential compounds that may be useful.  However, it showed how 354 
the counts per second of different m/z values changed before and after the diet.   355 
4.2 Linking to metabolism and the gut microbiome 356 
What multivariate analysis indicated is a metabolic or metabolomic difference in the profiles of ITP 357 
sufferers and healthy controls.  Multivariate data analysis showed that with a specificity of 87% and a 358 
sensitivity of 88%, samples from ITP sufferers can be distinguished from healthy controls with a 359 
percentage correctly classified with an accuracy of 88%. This means that the test could correctly 360 
differentiate 88% of the samples into either the ITP group or the control group.  This is potentially 361 
useful due to the fact ITP is a multifactorial disease and so difficult to diagnose.  If a method was 362 
available to help identify a certain metabolomic pattern in a person to suggest ITP – along with their 363 
presenting symptoms – it could help faster and less invasive diagnosis.  Aside from the diagnostic 364 
possibilities, the differences in the headspace of urine in ITP patients and controls demonstrates a 365 
clear metabolic difference in these subjects and this could then lead to a greater understanding of the 366 
origin of this debilitating condition. 367 
One possibility is that these differences result from changes in gut flora in ITP patients. The 368 
‘microbiomial relationship’ can become imbalanced via various internal and external factors.  Evidence 369 
suggests that much of this impact is mediated through diet and also suggests that the gut microbes 370 
can influence what the human host is able to extract from its diet, including energetically (31).  The 371 
intestinal microbiome has a high level of metabolic activity and diet, genetic factors, bodily changes 372 
(e.g. pregnancy), ageing, environment, chemical therapies and pharmacology can all affect it (32). In 373 
turn, the microbiome can have an effect not only on the gut itself but also on the immune response 374 
and immune system. 375 
These bacteria coexist in a complex mutually beneficial relationship which is physiologically important 376 
to host-microbe interactions in the gut in both directions (33).   If the bacterial profile changes, it can 377 
lead to added issues for the host including possible changes in fermentation in the gut.  If the microbial 378 
community is maladapted to its environment, it will actually impair all these processes and result in 379 
disease states including allergy, obesity, diabetes, rheumatoid arthritis (RA), cancer and inflammatory 380 
bowel disease (34).   381 
Cordain et al. in 2000 review how dietary lectins interact with enterocytes and lymphocytes to 382 
facilitate the translocation of dietary and gut-derived pathogen antigens into the peripheral tissues.  383 
This in turn causes persistent peripheral antigenic stimulation.  In genetically susceptible individuals, 384 
this antigenic stimulation could result in expression of overt RA via molecular mimicry, a factor which 385 
is also thought to play a role in ITP.  386 
It is therefore possible that such factors can also be implicated in conditions such as ITP.  One case of 387 
ITP highlighted was show by Borody et al in 2011.  Here a patient had presented with chronic relapsing 388 
ulcerative colitis with concomitant ITP.  This patient was offered faecal microbiota transplant (FMT) 389 
and accepted the offer.  The mean platelet count prior to FMT was below 100,000 per µl, following 390 
recurrent FMT the platelet count increased to 168,000 per µl then onto a steady progression to a 391 
normal range (mean 195,000 per µl, range 153,000-261,000 per µl).  They concluded from this 392 
‘unexpected’ side effect of FMT that some cases of ITP should be reassessed as arising from an 393 
‘infection’ in the gut microbiota (35). 394 
The findings of this study suggest further research is required into the gut microbiome of ITP patients.  395 
With work having been carried out by van der Waaji et al. in 2004 which showed that patients with 396 
IBD had an increased percentage of immunoglobulin-coated faecal anaerobic bacteria in both active 397 
disease, and just after remission, this area would be extremely pertinent to follow up with in ITP.   398 
It is also pertinent to mention the fact the ITP group was compared to a healthy volunteer group.  The 399 
intent of this was to examine differences and similarities between groups not suggest it is suitable at 400 
this point as a diagnostic test.  A further study to compare the ITP group to a group with co-related 401 
diseases would be beneficial to also show how these metabolomic changes occur in diseased groups 402 
and if they follow a similar pattern to the ITP group. 403 
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